Ensuring adequate manufacturing capacity for recombinant and monoclonal antibodies is one of the greatest challenges facing the biotech industry. The following factors should be taken into account when designing product development and production strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carson, K. Flexibility—the guiding principle for antibody manufacturing. Nat Biotechnol 23, 1054–1058 (2005). https://doi.org/10.1038/nbt0905-1054
Issue Date:
DOI: https://doi.org/10.1038/nbt0905-1054
This article is cited by
-
Expanded bed adsorption of albumin and immunoglobulin G from human serum onto a cation exchanger mixed mode adsorbent
Adsorption (2018)
-
Effects of carboxypeptidase B treatment and elevated temperature on recombinant monoclonal antibody charge variants in cation-exchange chromatography analysis
Archives of Pharmacal Research (2016)
-
High-throughput profiling of N-linked oligosaccharides in therapeutic antibodies using a microfluidic CD platform and MALDI-MS
Analytical and Bioanalytical Chemistry (2011)
-
Computational fluid dynamics modeling of an inverted frustoconical shaking bioreactor for mammalian cell suspension culture
Biotechnology and Bioprocess Engineering (2011)
-
Potent antibody therapeutics by design
Nature Reviews Immunology (2006)